サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1519678

ウイルスベクター製造市場レポート：タイプ、疾患、用途、エンドユーザー、地域別、2024年～2032年

Viral Vector Manufacturing Market Report by Type, Disease, Application, End User, and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 138 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
ウイルスベクター製造市場レポート：タイプ、疾患、用途、エンドユーザー、地域別、2024年～2032年
出版日: 2024年07月01日
発行: IMARC
ページ情報: 英文 138 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ウイルスベクター製造の世界市場規模は、2023年に12億10万米ドルに達しました。今後、IMARC Groupは、市場は2032年までに76億8,160万米ドルに達し、2024年から2032年の間に22.4%の成長率（CAGR）を示すと予測しています。

ウイルスベクターは、分子生物学者が細胞内に遺伝物質を送達するために使用するツールです。遺伝子疾患を治療するために欠陥のある遺伝子を置き換えたり、自然感染を模倣して免疫反応を引き起こすために病原性抗原を発現・提示するために使用されます。腫瘍細胞を標的にして死滅させる腫瘍溶解療法にも広く用いられています。このほか、心臓疾患、代謝性疾患、神経変性疾患など、さまざまな疾患の治療に役立つことから、生命科学研究、遺伝子治療、ワクチン学などにも幅広く応用されています。現在、遺伝子の突然変異や体内の染色体の損傷に起因する遺伝性疾患の有病率が上昇しているため、ウイルスベクター製造が増加しています。

ウイルスベクター製造市場動向：

個人のアルコール消費量の増加や座りがちなライフスタイルによるがん患者の増加は、市場の成長に寄与する主な要因の一つです。さらに、世界中でウイルスベクターに関する臨床研究が増加しています。これは、新規ドラッグデリバリーにおけるウイルスベクターの利用の増加とともに、市場にプラスの影響を与えています。これに加えて、ウイルスベクターはウイルス無効化配列の効率的なキャリアであり、ヒト造血幹細胞（HSCs）にHIV阻害導入遺伝子を送達するために使用されています。さらに、いくつかの国の政府は、ウイルスベクターワクチンに対する人々の意識を高めるためのキャンペーンを開始しています。また、承認プロセスの迅速化など、規制環境の改善も進められています。さらに、主要な市場参入企業は、世界中で製造能力増強のための投資を積極的に行っています。また、これらの企業は合併・買収（M&A）にも積極的に取り組んでおり、全体的な売上高と収益性の向上が見込まれています。

本レポートで扱う主な質問

  • 2023年の世界のウイルスベクター製造市場の市場規模は？
  • 2024-2032年の世界のウイルスベクター製造市場の予想成長率は？
  • 世界のウイルスベクター製造市場に対するCOVID-19の影響は？
  • 世界のウイルスベクター製造市場を牽引する主要因は？
  • 世界のウイルスベクター製造市場のタイプ別内訳は？
  • 世界のウイルスベクター製造市場の疾患別内訳は？
  • 世界のウイルスベクター製造市場の主要地域は？
  • 世界のウイルスベクター製造市場の主要プレイヤー／企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界のウイルスベクター製造市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：タイプ別

  • アデノウイルスベクター
    • 市場動向
    • 市場予測
  • アデノ随伴ウイルスベクター
    • 市場動向
    • 市場予測
  • レンチウイルスベクター
    • 市場動向
    • 市場予測
  • レトロウイルスベクター
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳：疾患別

  • がん
    • 市場動向
    • 市場予測
  • 遺伝性疾患
    • 市場動向
    • 市場予測
  • 感染症
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳：用途別

  • 遺伝子治療
    • 市場動向
    • 市場予測
  • ワクチン
    • 市場動向
    • 市場予測

第9章 市場内訳：エンドユーザー別

  • 製薬・バイオ医薬品企業
    • 市場動向
    • 市場予測
  • 研究機関
    • 市場動向
    • 市場予測

第10章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第11章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Cognate BioServices Inc.（Charles River Laboratories International Inc.）
    • F. Hoffmann-La Roche AG
    • FinVector Oy
    • FUJIFILM Holdings Corporation
    • Kaneka Eurogentec S.A.（Kaneka Corporation）
    • Lonza Group AG
    • Merck KGaA
    • Oxford Biomedica plc
    • REGENXBIO Inc.
    • Sanofi S.A.
    • Thermo Fisher Scientific Inc.
    • uniQure N.V.
図表

List of Figures

  • Figure 1: Global: Viral Vector Manufacturing Market: Major Drivers and Challenges
  • Figure 2: Global: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2018-2023
  • Figure 3: Global: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 4: Global: Viral Vector Manufacturing Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Viral Vector Manufacturing Market: Breakup by Disease (in %), 2023
  • Figure 6: Global: Viral Vector Manufacturing Market: Breakup by Application (in %), 2023
  • Figure 7: Global: Viral Vector Manufacturing Market: Breakup by End User (in %), 2023
  • Figure 8: Global: Viral Vector Manufacturing Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Viral Vector Manufacturing (Adenoviral Vectors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Viral Vector Manufacturing (Adenoviral Vectors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Viral Vector Manufacturing (Adeno-associated Viral Vectors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Viral Vector Manufacturing (Adeno-associated Viral Vectors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Viral Vector Manufacturing (Lentiviral Vectors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Viral Vector Manufacturing (Lentiviral Vectors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Viral Vector Manufacturing (Retroviral Vectors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Viral Vector Manufacturing (Retroviral Vectors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Viral Vector Manufacturing (Other Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Viral Vector Manufacturing (Other Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Viral Vector Manufacturing (Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Viral Vector Manufacturing (Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Viral Vector Manufacturing (Genetic Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Viral Vector Manufacturing (Genetic Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Viral Vector Manufacturing (Infectious Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Viral Vector Manufacturing (Infectious Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Viral Vector Manufacturing (Other Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Viral Vector Manufacturing (Other Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Viral Vector Manufacturing (Gene Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Viral Vector Manufacturing (Gene Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Viral Vector Manufacturing (Vaccinology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Viral Vector Manufacturing (Vaccinology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Viral Vector Manufacturing (Pharmaceutical and Biopharmaceutical Companies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Viral Vector Manufacturing (Pharmaceutical and Biopharmaceutical Companies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Viral Vector Manufacturing (Research Institutes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Viral Vector Manufacturing (Research Institutes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: North America: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: North America: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: United States: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: United States: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Canada: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Canada: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Asia-Pacific: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Asia-Pacific: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: China: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: China: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Japan: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Japan: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: India: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: India: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: South Korea: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: South Korea: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Australia: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Australia: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Indonesia: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Indonesia: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Others: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Others: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Europe: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Europe: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Germany: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Germany: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: France: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: France: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: United Kingdom: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: United Kingdom: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Italy: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Italy: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Spain: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Spain: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Russia: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Russia: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Others: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Others: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Latin America: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Latin America: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Brazil: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Brazil: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Mexico: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Mexico: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Others: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Others: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Middle East and Africa: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Middle East and Africa: Viral Vector Manufacturing Market: Breakup by Country (in %), 2023
  • Figure 83: Middle East and Africa: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 84: Global: Viral Vector Manufacturing Industry: SWOT Analysis
  • Figure 85: Global: Viral Vector Manufacturing Industry: Value Chain Analysis
  • Figure 86: Global: Viral Vector Manufacturing Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Viral Vector Manufacturing Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Viral Vector Manufacturing Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Viral Vector Manufacturing Market Forecast: Breakup by Disease (in Million US$), 2024-2032
  • Table 4: Global: Viral Vector Manufacturing Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 5: Global: Viral Vector Manufacturing Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 6: Global: Viral Vector Manufacturing Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Viral Vector Manufacturing Market: Competitive Structure
  • Table 8: Global: Viral Vector Manufacturing Market: Key Players
目次
Product Code: SR112024A5016

The global viral vector manufacturing market size reached US$ 1,200.1 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 7,681.6 Million by 2032, exhibiting a growth rate (CAGR) of 22.4% during 2024-2032.

A viral vector is a tool used by molecular biologists for delivering genetic materials into cells. It is used to replace defective genes for curing genetic disorders and express and present pathogenic antigens for generating an immune response by mimicking a natural infection. It is widely employed in oncolytic therapies to target and kill tumor cells. Besides this, as it assists in treating different diseases, such as heart defects, metabolic diseases, and neurodegenerative disorders, it finds extensive applications in life science research, gene therapy and vaccinology. At present, there is a rise in viral vector manufacturing on account of the rising prevalence of genetic disorders due to a combination of gene mutations and damaged chromosomes in the body.

Viral Vector Manufacturing Market Trends:

The increasing cancer patients due to the rising alcohol consumption and sedentary lifestyles of individuals represents one of the key factors contributing to the growth of the market. In addition, there is a rise in the number of clinical studies undertaken on viral vectors across the globe. This, along with the growing utilization of viral vectors in novel drug delivery, is positively influencing the market. Besides this, they are efficient carriers of virus-disabling sequences and are used to deliver HIV-inhibiting transgenes to human hematopoietic stem cells (HSCs). Additionally, governments of several countries are launching campaigns to generate awareness about viral vector vaccines among individuals. They are also improving the regulatory environment via changes, such as fast-track approval processes. Furthermore, key market players are extensively investing in capacity expansion for manufacturing activities around the world. These players are also indulging in mergers and acquisitions (M&A), which is projected to increase their overall sales and profitability.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global viral vector manufacturing market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, disease, application and end user.

Breakup by Type:

Adenoviral Vectors

Adeno-associated Viral Vectors

Lentiviral Vectors

Retroviral Vectors

Others

Breakup by Disease:

Cancer

Genetic Disorders

Infectious Diseases

Others

Breakup by Application:

Gene Therapy

Vaccinology

Breakup by End User:

Pharmaceutical and Biopharmaceutical Companies

Research Institutes

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Cognate BioServices Inc. (Charles River Laboratories International Inc.), F. Hoffmann-La Roche AG, FinVector Oy, FUJIFILM Holdings Corporation, Kaneka Eurogentec S.A. (Kaneka Corporation), Lonza Group AG, Merck KGaA, Oxford Biomedica plc, REGENXBIO Inc., Sanofi S.A., Thermo Fisher Scientific Inc. and uniQure N.V.

Key Questions Answered in This Report

  • 1. What was the size of the global viral vector manufacturing market in 2023?
  • 2. What is the expected growth rate of the global viral vector manufacturing market during 2024-2032?
  • 3. What has been the impact of COVID-19 on the global viral vector manufacturing market?
  • 4. What are the key factors driving the global viral vector manufacturing market?
  • 5. What is the breakup of the global viral vector manufacturing market based on the type?
  • 6. What is the breakup of the global viral vector manufacturing market based on the disease?
  • 7. What is the breakup of the global viral vector manufacturing market based on the application?
  • 8. What are the key regions in the global viral vector manufacturing market?
  • 9. Who are the key players/companies in the global viral vector manufacturing market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Viral Vector Manufacturing Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Adenoviral Vectors
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Adeno-associated Viral Vectors
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Lentiviral Vectors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Retroviral Vectors
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Disease

  • 7.1 Cancer
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Genetic Disorders
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Infectious Diseases
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Gene Therapy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Vaccinology
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Pharmaceutical and Biopharmaceutical Companies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Research Institutes
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Cognate BioServices Inc. (Charles River Laboratories International Inc.)
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
    • 15.3.2 F. Hoffmann-La Roche AG
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
    • 15.3.3 FinVector Oy
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 FUJIFILM Holdings Corporation
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Kaneka Eurogentec S.A. (Kaneka Corporation)
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
    • 15.3.6 Lonza Group AG
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Merck KGaA
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Oxford Biomedica plc
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 REGENXBIO Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Sanofi S.A.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Thermo Fisher Scientific Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 uniQure N.V.
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials